应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02696 复宏汉霖
休市中 08-23 16:08:27
22.900
-0.150
-0.65%
最高
23.000
最低
22.800
成交量
16.88万
今开
23.000
昨收
23.050
日振幅
0.87%
总市值
124.46亿
流通市值
37.43亿
总股本
5.43亿
成交额
387.33万
换手率
0.10%
流通股本
1.63亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
“中国籍”单抗生物类似药“出海”再获重要进展!复宏汉霖曲妥珠单抗在加拿大获批上市
浦东发布 · 08-23 19:24
“中国籍”单抗生物类似药“出海”再获重要进展!复宏汉霖曲妥珠单抗在加拿大获批上市
复宏汉霖(02696):HLX02(注射用曲妥珠单抗,加拿大商品名ADHEROZA)获加拿大卫生部(HEALTH CANADA)批准用于早期乳腺癌、转移性乳腺癌及转移性胃癌治疗
智通财经 · 08-22 17:45
复宏汉霖(02696):HLX02(注射用曲妥珠单抗,加拿大商品名ADHEROZA)获加拿大卫生部(HEALTH CANADA)批准用于早期乳腺癌、转移性乳腺癌及转移性胃癌治疗
复宏汉霖(02696.HK):HLX02获加拿大批准用于早期乳腺癌等治疗
阿斯达克财经 · 08-22 17:45
复宏汉霖(02696.HK):HLX02获加拿大批准用于早期乳腺癌等治疗
复宏汉霖与甫康药业达成奈拉替尼全球战略合作
美通社 · 08-20
复宏汉霖与甫康药业达成奈拉替尼全球战略合作
复宏汉霖(02696.HK)将于8月26日举行董事会会议以审批中期业绩
格隆汇 · 08-14
复宏汉霖(02696.HK)将于8月26日举行董事会会议以审批中期业绩
复宏汉霖(02696.HK)HLX53联合汉斯状及汉贝泰临床研究完成首例患者给药
阿斯达克财经 · 08-08
复宏汉霖(02696.HK)HLX53联合汉斯状及汉贝泰临床研究完成首例患者给药
复宏汉霖(02696.HK):HLX53(抗TIGIT的Fc融合蛋白)联合汉斯状(斯鲁利单抗注射液)及汉贝泰(贝伐珠单抗注射液)一线治疗局部晚期或转移性肝细胞癌的2期临床研究于中国境内完成首例患者给药
格隆汇 · 08-08
复宏汉霖(02696.HK):HLX53(抗TIGIT的Fc融合蛋白)联合汉斯状(斯鲁利单抗注射液)及汉贝泰(贝伐珠单抗注射液)一线治疗局部晚期或转移性肝细胞癌的2期临床研究于中国境内完成首例患者给药
复宏汉霖(02696):HLX53联合汉斯状®及汉贝泰®一线治疗局部晚期或转移性肝细胞癌的2期临床研究于中国境内完成首例患者给药
智通财经 · 08-08
复宏汉霖(02696):HLX53联合汉斯状®及汉贝泰®一线治疗局部晚期或转移性肝细胞癌的2期临床研究于中国境内完成首例患者给药
复宏汉霖“汉斯状?”多项最新研究数据即将公布
药智网 · 08-06
复宏汉霖“汉斯状?”多项最新研究数据即将公布
科兴制药重磅品种登陆欧盟!齐鲁、复宏汉霖、基石、亿帆,欧洲成出海“梦想之地”?
医药经济报 · 08-03
科兴制药重磅品种登陆欧盟!齐鲁、复宏汉霖、基石、亿帆,欧洲成出海“梦想之地”?
复宏汉霖07月25日遭主力抛售216万元 环比增加535.29%
自选股智能写手 · 07-25
复宏汉霖07月25日遭主力抛售216万元 环比增加535.29%
【中信证券:予复星医药“买入”评级 目标价32港元】金十数据7月25日讯,中信证券发表复星医药(02196.HK)最新研报显示,随着新冠相关业务负面影响出清,复星医药经营拐点明确,单季度盈利已回到疫情前水准,随着业务聚焦,利润率有望逐步改善。
美港电讯 · 07-25
【中信证券:予复星医药“买入”评级 目标价32港元】金十数据7月25日讯,中信证券发表复星医药(02196.HK)最新研报显示,随着新冠相关业务负面影响出清,复星医药经营拐点明确,单季度盈利已回到疫情前水准,随着业务聚焦,利润率有望逐步改善。
【中信证券:予复星医药“买入”评级 目标价32港元】7月25日讯,中信证券发表复星医药(02196.HK)最新研报显示,随着新冠相关业务负面影响出清,复星医药经营拐点明确,单季度盈利已回到疫情前水准,随着业务聚焦,利润率有望逐步改善。
汇通网 · 07-25
【中信证券:予复星医药“买入”评级 目标价32港元】7月25日讯,中信证券发表复星医药(02196.HK)最新研报显示,随着新冠相关业务负面影响出清,复星医药经营拐点明确,单季度盈利已回到疫情前水准,随着业务聚焦,利润率有望逐步改善。
复宏汉霖07月23日获主力加仓38万元 环比增加442.86%
自选股智能写手 · 07-23
复宏汉霖07月23日获主力加仓38万元 环比增加442.86%
复宏汉霖(02696)出现大手成交76.61万股,成交价$22.568,涉资1.729千万
阿斯达克财经 · 07-23
复宏汉霖(02696)出现大手成交76.61万股,成交价$22.568,涉资1.729千万
18A市值半年考!君圣泰、圣诺医药跌幅近九成,科伦博泰、复宏汉霖、亚盛医药涨幅前三
医药经济报 · 07-20
18A市值半年考!君圣泰、圣诺医药跌幅近九成,科伦博泰、复宏汉霖、亚盛医药涨幅前三
复宏汉霖07月17日主力资金流出163万元 连续3日减仓
自选股智能写手 · 07-17
复宏汉霖07月17日主力资金流出163万元 连续3日减仓
复宏汉霖07月16日遭主力抛售354万元 环比增加543.64%
自选股智能写手 · 07-16
复宏汉霖07月16日遭主力抛售354万元 环比增加543.64%
【林利军增持复宏汉霖(02696.HK)111.25万股 每股作价约22.82港元】智通财经APP获悉,香港联交所最新资料显示,7月10日,林利军增持复宏汉霖(02696.
智通财经 · 07-11
【林利军增持复宏汉霖(02696.HK)111.25万股 每股作价约22.82港元】智通财经APP获悉,香港联交所最新资料显示,7月10日,林利军增持复宏汉霖(02696.
林利军增持复宏汉霖(02696)111.25万股 每股作价约22.82港元
智通财经 · 07-11
林利军增持复宏汉霖(02696)111.25万股 每股作价约22.82港元
暂无数据
公司概况
公司名称:
复宏汉霖
所属市场:
SEHK
上市日期:
--
主营业务:
上海复宏汉霖生物技术股份有限公司是一家主要从事单克隆抗体产品的研发、生产及销售业务的中国公司。该公司的主要产品包括利妥昔单抗注射液HLX01(汉利康)、赫赛汀(曲妥珠单抗)生物类似药HLX02、修美乐(阿达木单抗)生物类似药HLX03和安维汀(贝伐珠单抗)生物类似药HLX04以及候选生物创新药,包括HLX06(一种新型VEGFR2抑制剂)、HLX07(一种EGFR抑制剂)、HLX10(一种新型PD-1抑制剂)、HLX20(一种新型PD-L1抑制剂)及HLX22(一种新型HER2抑制剂)等。该公司还提供相关技术服务。该公司主要在中国境内和美国开展业务。
发行价格:
--
{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":22.9,"timestamp":1724400507031,"preClose":23.05,"halted":0,"volume":168800,"delay":0,"floatShares":163428541,"shares":543494853,"eps":1.1013112,"marketStatus":"休市中","marketStatusCode":7,"change":-0.15,"latestTime":"08-23 16:08:27","open":23,"high":23,"low":22.8,"amount":3873273,"amplitude":0.008677,"askPrice":23,"askSize":90100,"bidPrice":22.9,"bidSize":19500,"shortable":0,"etf":0,"ttmEps":1.0958265438980845,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"listingDate":1569340800000,"adjPreClose":23.05,"openAndCloseTimeList":[[1724376600000,1724385600000],[1724389200000,1724400000000]],"volumeRatio":0.48759802515470824,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696/tweets","defaultTab":"tweets","newsList":[{"id":"2461627525","title":"“中国籍”单抗生物类似药“出海”再获重要进展!复宏汉霖曲妥珠单抗在加拿大获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2461627525","media":"浦东发布","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461627525?lang=zh_cn&edition=full","pubTime":"2024-08-23 19:24","pubTimestamp":1724412281,"startTime":"0","endTime":"0","summary":"汉曲优是在中国、欧盟、美国获批的“中国籍”单抗生物类似药,分别于2020年7月、2020年8月和2024年4月获得欧盟委员会、中国国家药品监督管理局和美国食品药品监督管理局批准上市。此次汉曲优在加拿大获批,主要基于复宏汉霖递交的全面的分析结果、临床前比对研究及临床比对研究数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082319271995b8098a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082319271995b8098a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2461395492","title":"复宏汉霖(02696):HLX02(注射用曲妥珠单抗,加拿大商品名ADHEROZA)获加拿大卫生部(HEALTH CANADA)批准用于早期乳腺癌、转移性乳腺癌及转移性胃癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2461395492","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461395492?lang=zh_cn&edition=full","pubTime":"2024-08-22 17:45","pubTimestamp":1724319926,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复宏汉霖 发布公告,内容有关公司与Intas Pharmaceuticals Limited订立一份许可协议,据此,公司同意授予Intas及其附属公司一项独家许可,供其于美国及加拿大商业化HLX02。近日,Accord收到加拿大卫生部的符合条件通知,150mg/瓶、420mg/瓶两种规格的HLX02获加拿大卫生部批准用于早期乳腺癌、转移性乳腺癌及转移性胃癌治疗,其于加拿大获批的商品名为Adheroza。本次获批,将进一步推动公司国际化布局的进程,提升公司产品的国际影响力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1168522.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2461396337","title":"复宏汉霖(02696.HK):HLX02获加拿大批准用于早期乳腺癌等治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2461396337","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461396337?lang=zh_cn&edition=full","pubTime":"2024-08-22 17:45","pubTimestamp":1724319900,"startTime":"0","endTime":"0","summary":"复宏汉霖(02696.HK) 公布,商务合作伙伴Accord收到加拿大卫生部(Health Canada)的符合条件通知,150mg/瓶、420mg/瓶两种规格的HLX02(注射用曲妥珠单抗)获加拿大卫生部(Health Canada)批准用于早期乳腺癌、转移性乳腺癌及转移性胃癌治疗,其于加拿大获批的商品名为Adheroza。(ha/u)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200928110330858_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200928110330858_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1374183/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2460009595","title":"复宏汉霖与甫康药业达成奈拉替尼全球战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2460009595","media":"美通社","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460009595?lang=zh_cn&edition=full","pubTime":"2024-08-20 20:53","pubTimestamp":1724158380,"startTime":"0","endTime":"0","summary":"上海2024年8月20日 /美通社/ -- 2024年8月19日,复宏汉霖与甫康(上海)健康科技有限责任公司宣布达成战略合作。复宏汉霖获得由甫康药业自主开发的首个产品马来酸奈拉替尼片在中国的商业化独占权利以及在约定海外国家和地区的独家谈判和附条件许可权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4487478_ZH87478_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1235294995.USD","BK4560","BK4020","NVAX","LU0868494617.USD","LU1430594728.SGD","LU0234572021.USD","LU1599440770.SGD","IE00BKVL7J92.USD","SG9999002224.SGD","LU0868494708.USD","LU1059921491.USD","LU1571399168.USD","BK4515","LU1585245621.USD","BK4579","LU1894683264.USD","LU0731783394.SGD","BK4585","LU1506573853.SGD","IE00B3T34201.USD","LU1066051498.USD","BK4581","LU1244550221.USD","LU1823568750.SGD","IE00BFXG1179.USD","LU1894683348.USD","LU2286300806.USD","BK4527","BK4588","SG9999001424.SGD","SG9999001440.SGD","SG9999002232.USD","LU1046421795.USD","02696","IE00BSNM7G36.USD","BK1161","BK4534","LU1066053197.SGD","BK4550","LU0942090050.USD","BK4533","LU1244550494.USD","LU0348723411.USD","BK4525","IE00BZ1G4Q59.USD","LU0234570918.USD","LU1244550577.SGD"],"gpt_icon":1},{"id":"2459141215","title":"复宏汉霖(02696.HK)将于8月26日举行董事会会议以审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2459141215","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459141215?lang=zh_cn&edition=full","pubTime":"2024-08-14 17:00","pubTimestamp":1723626054,"startTime":"0","endTime":"0","summary":"格隆汇8月14日丨复宏汉霖(02696.HK)公告,公司将于2024年8月26日举行董事会会议,以供(其中包括)考虑及批准集团截至2024年6月30日止六个月的中期业绩公告及其刊发,以及考虑建议派付中期股息(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240814170054ab5da7ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240814170054ab5da7ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2458346994","title":"复宏汉霖(02696.HK)HLX53联合汉斯状及汉贝泰临床研究完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2458346994","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458346994?lang=zh_cn&edition=full","pubTime":"2024-08-08 23:56","pubTimestamp":1723132560,"startTime":"0","endTime":"0","summary":"复宏汉霖(02696.HK) 公布,HLX53联合汉斯状及汉贝泰一线治疗局部晚期或转移性肝细胞癌的II期临床研究于内地完成首例患者给药。本研究为一项随机、双盲、多中心的2期临床研究,旨在评估HLX53联合汉斯状及汉贝泰对比安慰剂联合汉斯状及汉贝泰在未经治疗的局部晚期或转移性肝细胞癌患者中的有效性、安全性和耐受性。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1370141/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2457393149","title":"复宏汉霖(02696.HK):HLX53(抗TIGIT的Fc融合蛋白)联合汉斯状(斯鲁利单抗注射液)及汉贝泰(贝伐珠单抗注射液)一线治疗局部晚期或转移性肝细胞癌的2期临床研究于中国境内完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2457393149","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457393149?lang=zh_cn&edition=full","pubTime":"2024-08-08 18:34","pubTimestamp":1723113288,"startTime":"0","endTime":"0","summary":"格隆汇8月8日丨复宏汉霖发布公告,近日,HLX53联合汉斯状及汉贝泰一线治疗局部晚期或转移性肝细胞癌的2期临床研究于中国境内完成首例患者给药。截至本公告日,于全球范围内尚无同类联合用药治疗方案获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808183448aefde9ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808183448aefde9ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2457439835","title":"复宏汉霖(02696):HLX53联合汉斯状®及汉贝泰®一线治疗局部晚期或转移性肝细胞癌的2期临床研究于中国境内完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2457439835","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457439835?lang=zh_cn&edition=full","pubTime":"2024-08-08 18:33","pubTimestamp":1723113201,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复宏汉霖 发布公告,近日,HLX53联合汉斯状 (汉斯状)及汉贝泰 (汉贝泰)一线治疗局部晚期或转移性肝细胞癌的2 期临床研究于中国境内完成首例患者给药。本研究为一项随机、双盲、多中心的2期临床研究,旨在评估HLX53联合汉斯状及汉贝泰对比安慰剂联合汉斯状及汉贝泰在未经治疗的局部晚期或转移性肝细胞癌患者中的有效性、安全性和耐受性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1161746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2457068981","title":"复宏汉霖“汉斯状?”多项最新研究数据即将公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2457068981","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457068981?lang=zh_cn&edition=full","pubTime":"2024-08-06 12:23","pubTimestamp":1722918188,"startTime":"0","endTime":"0","summary":"的三项最新研究结果将以壁报形式在本次大会上发布。H药是复宏汉霖自主研发的重组人源化抗PD-1单抗注射液,也是全球首个获批一线治疗小细胞肺癌的抗PD-1单抗。以临床需求为导向,公司围绕H药进行了差异化、多维度布局,广泛覆盖肺癌、消化道肿瘤等高发大癌种。肺癌是全球最常见的恶性肿瘤之一。截至目前,H药已有4项适应症获批上市,2项适应症上市申请分别在中国和欧盟获受理,10余项临床试验同步在全球开展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408061230429f1278bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408061230429f1278bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2456521265","title":"科兴制药重磅品种登陆欧盟!齐鲁、复宏汉霖、基石、亿帆,欧洲成出海“梦想之地”?","url":"https://stock-news.laohu8.com/highlight/detail?id=2456521265","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456521265?lang=zh_cn&edition=full","pubTime":"2024-08-03 15:52","pubTimestamp":1722671563,"startTime":"0","endTime":"0","summary":"在国际化浪潮下,欧洲正成为本土药企出海的下一个“梦想之地”。近年来,科兴制药积极推动欧盟市场的营销渠道布局和拓展,截至目前,其已与欧盟、加拿大、英国等发达市场及巴西、新加坡等新兴市场共47个国家和地区的合作伙伴签约。本次科兴制药白蛋白紫杉醇获得欧盟委员会批准上市后,产品可以在欧盟所有国家上市销售,将极大解决欧盟国家的供应缺口问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408031555189f0aff2a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408031555189f0aff2a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK0239","688136"],"gpt_icon":0},{"id":"2454466938","title":"复宏汉霖07月25日遭主力抛售216万元 环比增加535.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2454466938","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454466938?lang=zh_cn&edition=full","pubTime":"2024-07-25 16:16","pubTimestamp":1721895400,"startTime":"0","endTime":"0","summary":"07月25日, 复宏汉霖股价跌0.44%,报收22.40元,成交金额903万元,换手率0.25%,振幅0.44%,量比1.06。复宏汉霖今日主力资金净流出216万元,上一交易日主力净流出34万元,今日环比增加535.29%。该股近5个交易日下跌0.66%,主力资金累计净流出203万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出9856万元,其中净流出天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072516175095595c78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072516175095595c78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2454898179","title":"【中信证券:予复星医药“买入”评级 目标价32港元】金十数据7月25日讯,中信证券发表复星医药(02196.HK)最新研报显示,随着新冠相关业务负面影响出清,复星医药经营拐点明确,单季度盈利已回到疫情前水准,随着业务聚焦,利润率有望逐步改善。","url":"https://stock-news.laohu8.com/highlight/detail?id=2454898179","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454898179?lang=zh_cn&edition=full","pubTime":"2024-07-25 10:23","pubTimestamp":1721874180,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0187","BK0183","02696","BK1593","159992","BK0060","BK1574","BK0012","BK0028","BK0239","BK0196","600196","02196","06978","BK0096","BK1161","BK1515","BK0175","BK0188","BK1191"],"gpt_icon":0},{"id":"2454383893","title":"【中信证券:予复星医药“买入”评级 目标价32港元】7月25日讯,中信证券发表复星医药(02196.HK)最新研报显示,随着新冠相关业务负面影响出清,复星医药经营拐点明确,单季度盈利已回到疫情前水准,随着业务聚焦,利润率有望逐步改善。","url":"https://stock-news.laohu8.com/highlight/detail?id=2454383893","media":"汇通网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454383893?lang=zh_cn&edition=full","pubTime":"2024-07-25 10:23","pubTimestamp":1721874180,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://kx.fx678.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_huitong","symbols":["BK1515","BK0060","BK0188","BK1161","159992","BK0175","BK0012","06978","02196","BK1574","BK1593","BK0239","BK1191","BK0096","BK0196","BK0183","600196","BK0187","02696","BK0028"],"gpt_icon":0},{"id":"2453970704","title":"复宏汉霖07月23日获主力加仓38万元 环比增加442.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453970704","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453970704?lang=zh_cn&edition=full","pubTime":"2024-07-23 16:15","pubTimestamp":1721722515,"startTime":"0","endTime":"0","summary":"07月23日, 复宏汉霖股价跌0.22%,报收22.45元,成交金额2214万元,换手率0.60%,振幅0.67%,量比2.43。复宏汉霖今日主力资金净流入38万元,上一交易日主力净流入7万元,今日环比增加442.86%。该股近5个交易日下跌0.44%,主力资金累计净流出80万元;近20日主力资金累计净流出1.72亿元,其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407231615249552626c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407231615249552626c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2453264507","title":"复宏汉霖(02696)出现大手成交76.61万股,成交价$22.568,涉资1.729千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2453264507","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453264507?lang=zh_cn&edition=full","pubTime":"2024-07-23 09:03","pubTimestamp":1721696580,"startTime":"0","endTime":"0","summary":"[大手成交]复宏汉霖(02696)在上午09:03出现大手成交,成交量为76.61万,成交价为港币$22.568,涉资1.729千万。至目前为止,股价无升跌,今日最高价为$22.568,而最低价为$22.568,总成交量为76.61万股,总成交金额港币$1.729千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2407233/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2452556532","title":"18A市值半年考!君圣泰、圣诺医药跌幅近九成,科伦博泰、复宏汉霖、亚盛医药涨幅前三","url":"https://stock-news.laohu8.com/highlight/detail?id=2452556532","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452556532?lang=zh_cn&edition=full","pubTime":"2024-07-20 13:31","pubTimestamp":1721453482,"startTime":"0","endTime":"0","summary":"截至7月19日中午,近半年来,总市值跌幅最大的十家企业分别是君圣泰医药、圣诺医药、健世科技、来凯医药、创胜集团、润迈德、康宁杰瑞制药、宜明昂科、德琪医药和兆科眼科。截至公告发布之日,圣诺医药仅赎回了20万美元。截至7月19日中午,科伦博泰、复宏汉霖、亚盛医药、欧康维视生物和东曜药业近半年总市值","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407201333569f6fe90d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407201333569f6fe90d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","02511","02696","02257","06628","09877","01875","BK1574","02105","06855","BK1515"],"gpt_icon":0},{"id":"2452875101","title":"复宏汉霖07月17日主力资金流出163万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2452875101","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452875101?lang=zh_cn&edition=full","pubTime":"2024-07-17 16:16","pubTimestamp":1721204171,"startTime":"0","endTime":"0","summary":"07月17日, 复宏汉霖股价跌0.44%,报收22.45元,成交金额1156万元,换手率0.32%,振幅0.67%,量比0.67。复宏汉霖今日主力资金净流出163万元,连续3日净流出,上一交易日主力净流出354万元,今日环比减少53.95%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为80.00%,平均跌幅为3.16%。该股近5个交易日下跌1.10%,主力资金累计净流出353万元;近20日主力资金累计净流出1.73亿元,其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071716164195cd6c3d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071716164195cd6c3d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2451695727","title":"复宏汉霖07月16日遭主力抛售354万元 环比增加543.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2451695727","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451695727?lang=zh_cn&edition=full","pubTime":"2024-07-16 16:16","pubTimestamp":1721117813,"startTime":"0","endTime":"0","summary":"07月16日,复宏汉霖股价收平报22.55元,成交金额1878万元,换手率0.51%,振幅1.33%,量比0.99。复宏汉霖今日主力资金净流出354万元,上一交易日主力净流出55万元,今日环比增加543.64%。该股近5个交易日下跌0.88%,主力资金累计净流出590万元;近20日主力资金累计净流出1.71亿元,其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407161617229f54aaec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407161617229f54aaec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2450991356","title":"【林利军增持复宏汉霖(02696.HK)111.25万股 每股作价约22.82港元】智通财经APP获悉,香港联交所最新资料显示,7月10日,林利军增持复宏汉霖(02696.","url":"https://stock-news.laohu8.com/highlight/detail?id=2450991356","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450991356?lang=zh_cn&edition=full","pubTime":"2024-07-11 19:49","pubTimestamp":1720698559,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2450356913","title":"林利军增持复宏汉霖(02696)111.25万股 每股作价约22.82港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450356913","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450356913?lang=zh_cn&edition=full","pubTime":"2024-07-11 19:49","pubTimestamp":1720698559,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,香港联交所最新资料显示,7月10日,林利军增持复宏汉霖(02696)111.25万股,每股作价22.8237港元,总金额约为2539.14万港元。增持后最新持股数目约为915.57万股,最新持股比例为5.60%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","BK1161"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":0.0178},{"period":"3month","weight":0.2155},{"period":"6month","weight":0.7697},{"period":"1year","weight":1.1851},{"period":"ytd","weight":0.6475}],"compareEarnings":[{"period":"1week","weight":0.0104},{"period":"1month","weight":0.0174},{"period":"3month","weight":-0.0536},{"period":"6month","weight":0.053},{"period":"1year","weight":-0.0329},{"period":"ytd","weight":0.0331}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事单克隆抗体产品的研发、生产及销售业务的中国公司。该公司的主要产品包括利妥昔单抗注射液HLX01(汉利康)、赫赛汀(曲妥珠单抗)生物类似药HLX02、修美乐(阿达木单抗)生物类似药HLX03和安维汀(贝伐珠单抗)生物类似药HLX04以及候选生物创新药,包括HLX06(一种新型VEGFR2抑制剂)、HLX07(一种EGFR抑制剂)、HLX10(一种新型PD-1抑制剂)、HLX20(一种新型PD-L1抑制剂)及HLX22(一种新型HER2抑制剂)等。该公司还提供相关技术服务。该公司主要在中国境内和美国开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.004462},{"month":2,"riseRate":0.6,"avgChangeRate":0.003175},{"month":3,"riseRate":0.4,"avgChangeRate":-0.070667},{"month":4,"riseRate":0.8,"avgChangeRate":0.127521},{"month":5,"riseRate":0.4,"avgChangeRate":-0.068918},{"month":6,"riseRate":0.6,"avgChangeRate":0.1049},{"month":7,"riseRate":0.4,"avgChangeRate":0.0182},{"month":8,"riseRate":0.4,"avgChangeRate":-0.052521},{"month":9,"riseRate":0,"avgChangeRate":-0.17846},{"month":10,"riseRate":0.4,"avgChangeRate":-0.013739},{"month":11,"riseRate":0.8,"avgChangeRate":0.086734},{"month":12,"riseRate":0.8,"avgChangeRate":-0.01905}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}